Ifinatamab Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Pretreated Extensive-Stage SCLC August 19, 2025
Early Data Demonstrates Tuspetinib Improves SOC Treatment Across Diverse Populations of Newly Diagnosed AML in Ph 1/2 TUSCANY Trial August 19, 2025
Bexmarilimab to advance into registrational Ph 2/3 study in 1L HR-MDS after positive meeting with the FDA August 19, 2025
Patient deaths trigger discontinuation of Ph 1 trial from SGR-2921 Program in R/R AML and HR-MDS patients August 19, 2025
PADCEV Plus KEYTRUDA Significantly Improves Survival for Cisplatin-ineligible MIBC Patients When Given Before and After Surgery August 19, 2025
Discovery research reduced to support registrational trials for ORIC-944 and ORIC-114 August 19, 2025
CIT Therapeutics Forms Strategic Partnership with IFLI, Securing Up to $2.5M to Advance Novel Cancer Therapies August 19, 2025
BriaCell Selected for MSK’s 2025 Therapeutics Accelerator Program for Bria-OTS+ for metastatic breast cancer, prostate cancer, and other cancers August 19, 2025
Further development of PRT3789 in patients with biomarker selected SMARCA4-mutated cancers paused August 19, 2025
First Patient Dosed in Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated with ADCs August 19, 2025
CTMX-2051-101 study remains active and patients continue to be dosed with CX-2051 across all expansion doses August 19, 2025
IMvigor011 Bladder Cancer Trial Achieves Positive Results, with Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit August 19, 2025
ELI-002 Updated AMPLIFY-201 Ph 1 Follow-up Data published in Nature Medicine for MRD Positive, Adjuvant-Stage Patients August 19, 2025
Izalontamab Brengitecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Previously Treated Advanced EGFR-Mutated NSCLC August 19, 2025
Global Registrational Ph 3 Study of Lisaftoclax for 1L Higher-Risk MDS Cleared by US FDA and EMA August 19, 2025
German federal authority approves CTA to initiate Ph 1/2a trial of CC-38 in patients with metastatic CRC and metastatic prostate cancer August 19, 2025
